Therapeutic equivalence investigations: statistical considerations

Area of Science:

• Pharmacometrics
• Biostatistics
• Regulatory Science

Background:

• Therapeutic equivalence studies are critical for drug approval and generic substitution.
• Current methodologies face challenges in interpretation and application for regulatory reviewers.
• Ensuring consistent and reliable therapeutic equivalence assessments is paramount for patient safety and healthcare economics.

Purpose of the Study:

• To identify and discuss statistical challenges encountered by regulatory reviewers in therapeutic equivalence studies.
• To explore and present newer statistical methodologies that can enhance the investigation of therapeutic equivalence.
• To provide a statistical perspective on improving the rigor and clarity of therapeutic equivalence assessments.

Main Methods:

• Review of common statistical issues in therapeutic equivalence study designs and analyses.
• Exploration of advanced statistical techniques, such as Bayesian methods and meta-analysis, applied to therapeutic equivalence.
• Discussion of the implications of these statistical approaches for regulatory decision-making.

Main Results:

• Identified key statistical concerns including sample size determination, handling of multiplicity, and choice of statistical models.
• Highlighted the potential of novel statistical approaches to address limitations in traditional methods.
• Demonstrated how advanced statistical perspectives can lead to more robust evaluations of therapeutic equivalence.

Conclusions:

• Statistical considerations are central to the successful design and interpretation of therapeutic equivalence studies.
• Adoption of advanced statistical methods can improve the precision and reliability of therapeutic equivalence assessments.
• Further research and regulatory guidance on newer statistical approaches are warranted to optimize therapeutic equivalence evaluations.